🏛️ Verified NIH Record • Updated 2026-08-24

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors (NCT07383506)

A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Cogent Biosciences, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations

Who can join: Review the eligibility criteria below.

Location: HonorHealth Research Institute — Scottsdale, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (11 Sites)

  • HonorHealth Research Institute — Scottsdale, Arizona
  • START Los Angeles — Los Angeles, California
  • Sarah Cannon Research Institute (SCRI) at HealthONE-Denver — Denver, Colorado
  • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. — Tampa, Florida
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
  • START New Jersey, LLC — East Brunswick, New Jersey
  • SCRI Oncology Partners - Nashville — Nashville, Tennessee
  • NEXT Austin — Austin, Texas
  • START Mountain Region, LLC — West Valley City, Utah
  • NEXT Virginia — Fairfax, Virginia

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All PIK3CA Mutations clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗